Skip to main content
Clinical Trials/IRCT138904244380N2
IRCT138904244380N2
Completed
Phase 3

Determining the effect of Selenium supplementation on CD4+ T lymphocyte count in HIV+ patients refered to Iranian HIV/AIDS Research Center (IRCHA)

Vice Chancellor For Research, Tehran University of Medical Sciences0 sites100 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
HIV infection.
Sponsor
Vice Chancellor For Research, Tehran University of Medical Sciences
Enrollment
100
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice Chancellor For Research, Tehran University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria: Age 18\-60 years, Confirmed HIV\-1 infection with western blot test, receiving HAART, CD4 between 200 and 350, signing informed consent Exclusion criteria: Pregnancy, any other supplementation than Selinium, history of hypersensitivity to Selenium, unwilling to cooperate, any plan to leave Tehran during the next 9 months after beginning of the study, History of chronic kidney diseases

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials